Bovine Paratyphoid Vaccine, Inactivated Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a sterile whole-cell antigen concentrate of Salmonella enterica subsp. enterica serovar Dublin, standardized after inactivation to a minimum antigenic mass corresponding to 1.0×10⁹ cells per dose equivalent. The six downstream application scenarios below are restricted to commercially documented veterinary dosage-form routes and exclude human biologics, companion-animal vaccines, and live-attenuated formulations. Each scenario identifies the applicable regulatory framework, the addition ratio of the API in the finished formulation, the production-scale unit operations, and the terminal packaged article.

Production-scale blending of an injectable bacterin for dairy replacement heifers begins with the transfer of the API concentrate from a 1,500 L fermenter harvest through a disk-stack centrifuge at 12,000×g, followed by diafiltration against 0.01 M phosphate-buffered saline pH 7.2 until conductivity falls below 3.0 mS/cm. The standardized concentrate is inactivated with 0.3–0.5% v/v formaldehyde at 37±0.5°C for 24–48 h, after which residual formaldehyde is reduced to <0.05% w/v and verified by derivatization-HPLC. The formulation vessel, a 1,500 L jacketed stainless-steel tank with bottom-mounted rotor-stator disperser operated at 800–1,200 rpm and a 0.3 mm shear gap, receives 20–40% v/v API concentrate, phosphate-buffered saline to 70% of final volume, and 1.5–2.5 mg Al³⁺/mL aluminum hydroxide adjuvant via a loss-in-weight inline metering pump; after 45 min of recirculation mixing at 25±2°C, the batch is brought to final volume and homogenized at 1,200 rpm for 15 min. The final antigen load is 1.0×10⁹–5.0×10⁹ inactivated cells per 2.0 mL dose, with osmolality adjusted to 280–320 mOsm/kg and pH held at 7.0–7.4. Compliance for this injectable presentation includes EU GMP Annex 2 for biological active substances, EU Regulation 2019/6 for veterinary medicinal products, sterility testing per Ph. Eur. 2.6.1, bacterial endotoxin below 20 EU/dose per Ph. Eur. 2.6.14, residual formaldehyde per Ph. Eur. 2.4.18, and aluminum content per Ph. Eur. 2.5.13. Operational boundaries: the adjuvanted suspension must not be frozen, because freeze-thaw collapse of aluminum hydroxide flocs shifts the particle-size distribution to D90 >25 µm and produces syringe needle blockage; phosphate concentration above 50 mM must be avoided to prevent aluminum gel destabilization. Terminal packaged forms are 50 mL, 100 mL, and 250 mL multidose high-density polyethylene vials with bromobutyl rubber stoppers and aluminium flip-off seals, stored at 2–8°C.

What Limits Primary Drying Cycle Time for Lyophilized Bovine Paratyphoid Antigen?

Lyophilized single-dose presentations are selected when supply-chain temperature excursions above 25°C would compromise aluminum-adjuvanted suspensions. The liquid formulation is prepared by mixing 1 volume of API concentrate with 4 volumes of excipient solution containing 4.0–6.0% w/v trehalose dihydrate, 2.0–4.0% w/v mannitol, 1.0% w/v hydrolyzed gelatin, and 10 mM citrate buffer pH 6.8; the antigen load is 2.0×10⁹ inactivated cells per 5 mL vial after reconstitution. Filling into 5 mL type I glass vials occurs under ISO 14644-1:2015 Class 7 with partial stopper placement, and the vials are loaded onto stainless-steel lyophilizer shelves at a shelf temperature of 5±1°C. The freeze-drying cycle uses a freezing ramp of 0.5°C/min to -45°C and a 2 h hold, followed by primary drying at -30°C shelf and 80–120 µbar chamber pressure for 30–40 h; primary drying is the rate-limiting step because the amorphous mannitol-trehalose matrix collapses at product temperatures above -28°C, requiring careful control of the sublimation interface. Secondary drying at +25°C for 4 h reduces residual moisture to ≤3.0% w/w by Karl Fischer titration per Ph. Eur. 2.5.12. Reconstituted vials must be used within 4 h and must pass Ph. Eur. 2.6.1 sterility and Ph. Eur. 2.6.14 endotoxin limits after reconstitution; stability is evaluated under VICH GL3 conditions at 25°C/60% RH and 40°C/75% RH. Terminal packaged articles are single-dose 5 mL vials sealed with bromobutyl lyophilization stoppers and flip-off caps.

Mass vaccination of pre-ruminant calves through milk replacer requires the API to be converted into a water-dispersible granulated powder rather than a liquid broth, because milk replacer reconstitution plants operate at batch temperatures of 40–45°C and have no steam sterilization capability. The granulation process uses a top-spray fluid-bed system with inlet air temperature 65±2°C, product bed temperature 32–36°C, spray rate 250–300 g/min, and final granulate moisture 1.5–2.5% w/w; the granulation liquid contains 25–35% w/w API-loaded preblend, mannitol as water carrier, 2% w/w sodium carboxymethyl starch as disintegrant, and an 8% w/w citric acid–sodium bicarbonate effervescent pair to accelerate dispersibility in 40°C milk replacer. The oral dose target is 1.0×10⁹–2.0×10⁹ inactivated cells per 2 g granulate per calf, administered once daily for 3 consecutive days; the addition ratio in the final granulate is therefore 25–35% w/w antigen-loaded preblend, with the remainder consisting of mannitol, disintegrant, and effervescent salts. Microbiological quality of this non-sterile oral dosage form complies with Ph. Eur. 5.1.4 and the relevant EU Regulation 2019/6 provisions for oral veterinary medicines; dispersion in 500 mL water at 40°C is specified to occur within 3 min with a final residue <5% w/w on a 180 µm sieve. Processing limitation: the fluid-bed granulation must not exceed product temperature 36°C, because antigen denaturation increases by 0.6 log/hour when granulate temperature rises above 40°C. Published efficacy data for oral killed Salmonella Dublin antigen delivery through milk replacer is limited; the described formulation is based on killed bacterial oral antigen delivery models. Terminal packaged articles are 10 g aluminium-foil sachets and 500 g polyethylene terephthalate/aluminium/low-density polyethylene pouches.

When Feed-Grade Carriers Cross the 5% Molasses Threshold

For beef feedlot oral premix, dry carrier blending in a 500 L horizontal ribbon blender with a fill volume of 70%, agitator tip speed 1.5 m/s, and a 12 min mixing window is used to dilute the API into a calcium carbonate–wheat middlings carrier at an API addition ratio of 5.0×10⁸ inactivated cells per gram of premix; the premix is then incorporated into complete feed at 2–5 kg/ton to achieve a daily oral antigen exposure of 1.0×10⁹ cells per 350 kg animal. Sequential dilution is mandatory: the first preblend contains 20–30% w/w API adsorbed to 40–50% w/w calcium carbonate and 20–30% w/w wheat middlings, and the final premix is produced by passing the preblend through a comminuting mill fitted with a 0.8 mm screen before ribbon blending. Homogeneity is verified using a 10-point thief sampling plan with a coefficient of variation ≤8% and a 90/90 confidence criterion for at least 90% of samples falling within 90–110% of the label antigen activity. The compliance framework for feed-premix application includes Regulation (EC) No 183/2005 for feed hygiene, EU Regulation 2019/6 for veterinary medicinal premixes, and Ph. Eur. 5.1.4 for non-sterile microbial quality; if the premix is manufactured under US jurisdiction, 9 CFR 113.100 applies to the killed bacterial vaccine component. A documented operational boundary is that molasses-based carriers above 5% w/w are incompatible because they increase moisture and cause bridging in downstream micro-dosing augers; storage must be below 25°C and 60% RH to prevent antigen potency loss. Terminal packaged articles are 25 kg multi-wall paper bags with a 0.1 mm low-density polyethylene inner liner.

Tablet Compression Mechanics and Enteric Coating Integrity in Adult Cattle Boluses

Oral enteric-coated tablets for adult cattle are produced from a dry granulate obtained by roller compaction at roll pressure 35–55 MPa, roll speed 8–12 rpm, and screen milling at 0.8 mm; the tableting blend consists of 20–30% w/w antigen-loaded granulate, 45–55% w/w microcrystalline cellulose, 2–5% w/w croscarmellose sodium, and ≤0.5% w/w magnesium stearate. The compression step on a rotary tablet press with 20 mm concave tooling must maintain main compression force at 55±5 kN, corresponding to tablet hardness 80–120 N, because higher compression forces above 80 MPa induce antigen loss greater than 0.5 log; tablet friability is controlled to ≤1.0% per Ph. Eur. 2.9.7 and disintegration time in 0.1 M hydrochloric acid is specified to exceed 2 h, followed by release in phosphate buffer pH 6.8 within 60 min per Ph. Eur. 2.9.1. Enteric coating uses an aqueous Eudragit L 30 D-55 dispersion at 20% solids with inlet air temperature 45–50°C, bed temperature 28–32°C, pan speed 6–8 rpm, and a coating weight gain of 6–8%; triethyl citrate 10% w/w of polymer is the plasticizer. Uniformity of dosage units per Ph. Eur. 2.9.40 and microbial quality per Ph. Eur. 5.1.4 apply; because the API is heat-labile, solvent-based coating with methylene chloride is excluded. Where hard gelatin capsules replace tablets to avoid compression stress, size 000 hard gelatin capsules are filled to 700 mg at 20–25°C and ≤40% RH, then coated with the same enteric polymer at 6–8% weight gain. Published efficacy data for this specific enteric-coated killed Salmonella Dublin presentation in adult cattle is limited; the manufacturing constraints are derived from enteric antigen-delivery and veterinary tablet-processing data. Terminal packaged articles are 10-count cold-form aluminium foil blisters with desiccant sachets.

Autogenous bacterin lines for veterinary biologics facilities combine the API with Escherichia coli F5 and Clostridium perfringens type A toxoid in ratios of 20–30% v/v API, 10–15% v/v E. coli bacterin, and 5–10% v/v C. perfringens toxoid in a 200 L jacketed vessel stirred at 300 rpm at 4±2°C; the addition ratio is fixed by the prescribing veterinarian’s diagnostic isolate panel and is documented in the autogenous license submission. The blended product is filled directly without terminal sterilization, so the process relies on pre-sterilized components, ISO 14644-1:2015 Class 7 aseptic filling, and sterilizing-grade 0.2 µm filtration for all heat-stable buffers; the API itself is not filterable due to whole-cell particle size and is added aseptically. Compliance in the United States requires killed bacterial vaccine safety and potency testing under 9 CFR 113.100, and state-level autogenous biologic requirements govern release; in the EU, autogenous vaccines fall under EU Regulation 2019/6 and require batch-specific approval where national competent authorities permit. Sterility per Ph. Eur. 2.6.1, endotoxin <20 EU/mL per Ph. Eur. 2.6.14, and identity confirmation by slide agglutination with monovalent O-antigen serum are release tests; operational boundaries include avoiding freeze storage of liquid polyvalent bacterins and avoiding blending with saponin-based adjuvants that can precipitate Salmonella lipopolysaccharide. Terminal packaged articles are 100 mL and 250 mL multidose high-density polyethylene vials with grey butyl stoppers stored at 2–8°C.